Spirea Ltd

Spirea has developed an exciting and flexible new approach to building ADCs that allows more drug payload to be specifically directed to the target tumour cell. This results in an increase in therapeutic effect whilst substantially reducing debilitating side-effects. By delivering the right amount of the right drug to the right cells, Spirea’s proprietary technology will unlock a new generation of accessible, powerful and well-tolerated medicines for the treatment of a wide range of cancers.

Spirea will use its revolutionary technology to build a pipeline of proprietary and partnered ADC therapeutics. As well as developing its own drugs, the company plans to collaborate with partners on new programmes and to revive pre-existing preclinical and clinical-stage assets that have failed because of narrow therapeutic index.

Spirea was founded by Dr Myriam Ouberai (Chief Executive Officer), following her research at the Nanoscience Centre at the University of Cambridge. Myriam has extensive experience in biopharmaceuticals in both academia and industry. Dr Adam Collier (Chief Business Officer) has over 15 years’ experience in biotech management, business development and early-stage company formation, having held several senior positions at Medimmune, Ablynx and Isogenica. He was also Founder-Director of Horizon Discovery (AIM:HZD).